Abstract
Myasthenia gravis (MG) is often described as the prototype of an auto antibody-mediated autoimmune disease. The autoantibodies are directed against the nicotinic acetylcholine receptor on the skeletal muscle endplate, the disease is transmitted from mother to child and from humans to animals, and immunisation with acetylcholine receptor induces experimental myasthenia gravis in animals.1 The disease-specific autoantibodies are, however, found in conditions not accompanied by neuromuscular symptoms, as in healthy first-degree relatives to patients, in monoclonal gammopathies, in primary biliary cirrhosis and in thymomas. Despite extensive efforts to try to distinguish the disease-causing antibodies found in myasthenia with those found in other conditions, no clear difference between these antibodies has been found. These observations together with the rather bad correlation between the concentration of autoantibodies in serum and the clinical symptoms suggest that mechanisms other than these antibodies may contribute by modulating the effects of autoantibodies on the neuromuscular junction.
Keywords
- Primary Biliary Cirrhosis
- Acetylcholine Receptor
- Receptor Antibody
- Thymic Epithelial Cell
- Idiotypic Network
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Lefvert AK. Human and experimental myasthenia gravis. In: Coutinho A, Kazatchine M, Wiley-Liss, Inc. Eds. Autoimmunity: Physiology and Disease. New York 1994; 267-305.
Åhlberg RE, Pirkanen R, Lefvert AK. Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin. Immunol. Immunopathol. 1991; 60:93–105.
Dropcho EJ, Richman DP, Antel J, Arnason BGW. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann. Neurol. 1982; 11:456–462.
Zilko PJ, Dawkins RL, Holmes K, Witt C. Genetic control of suppressor lymphocyte function in myasthenia gravis: Relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies. Clin. Immunol. Immunopathol. 1979; 14:222–230.
Mischak RP, Dau PC, Gonzales RL, Spitler LE. In vitro testing of suppressor cell activity in myasthenia gravis. In: Dau PC, Ed. Plasmapheresis and the Immunobiology of myasthenia gravis. Houghton, Boston, 1979.
Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi BM, Toyka KV. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986; 36:618–621.
Hohlfeld R, Toyka KV, Tzartos SJ, Carson W, Conti-Tronconi BM. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit. Proc. Natl. Acad. Sci. USA 1987; 84:5379–5383.
Hohlfeld R, Toyka KV, Miner LL, Walgrave SL, Conti-Tronconi BM. Amphipatic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. J. Clin. Invest. 1988; 81:657–660.
Åhlberg R, Yi Q, Eng H, Pirskanen R, Lefvert AK. T-cell epitopes on the human acetylcholine receptor α-subunit residues 10–84 in myasthenia gravis. Scand. J. Immunol. 1992; 36:435–442.
Yi Q, Pirskanen R, Lefvert AK. Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J. Neuroimmunol 1993; 42:215–222.
Yi Q, Åhlberg R, Pirskanen R, Lefvert AK. Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells. J. Neuroimmunol. 1994; 50:177–186.
Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol. Today 1991; 12:256–257.
Del Prete GF, De Carli M, Mastromauro C, etals. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest. 1991; 88: 346–350.
Del Prete GF, De Carli M, Ricci M, Romagnani S. Helper activity for immunoglobulin synthesis of T helper type 1 (Thl) and Th2 human T cell clones: the help of Thl clones is limited by their cytolytic capacity. J. Exp. Med 1991; 174:809–813.
Yi Q, Ahlberg R, Pirskanen R, Lefvert AK. Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells. J. Neuroimmunol. 1994; 50:177–186.
Lefvert Ak, Sunden H, Holm G. Acetylcholine receptor antibodies and anti-idiotypic antibodies produced in blood lymphocyte cultures from patients with myasthenia gravis. Scand. J. Immunol. 1986; 23:655–662.
Lefvert AK. Idiotypes and anti-idiotypes of human autoantibodies to the acetylcholine receptor. In: Karger S, Ed. Monographs in allergy. Basel 1987; 22: 57-70.
Lefvert AK. The start of an autoimmune process: idiotypic networks during the development of myasthenia gravis. Ann. Inst. Pasteur 1988; 139:633–643.
Lefvert AK. Anti-idiotype antibodies in myasthenia gravis. In: Bona C, Ed. Biological applications of antiidiotypes. CRC Press Inc, Boca Raton, Fl. 1988; Vol IIC: 69-91.
Yi Q, Åhlberg R, Lefvert AK. T cells with specificity for idiotypic determinants on human monoclonal autoantibodies in myasthenia gravis. Res. immunol. 1992; 143:149–156.
Yi Q, Lefvert AK. Idiotypic and anti-idiotypic T and B lymphocytes in myasthenia gravis. J. Immunol. 1992; 149:3423–3426.
Yi Q, Lefvert AK. Idiotype-and anti-idiotype-reactive T lymphocytes in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper lymphocytes. J. Immunol. 1994; 153:3353–3359.
Lefvert AK, Holm G. Idiotypic network in myasthenia gravis demonstrated by human monoclonal B-cell lines. Scand. J. Immunol. 1987; 26:573.
Eng H, Magnusson Y, Matell G, Lefvert AK, Saponja R, Hoebeke J. β2-adrenergic receptor antibodies in myasthenia gravis. J. Autoimmunity 1992; 5:213–227.
Yi Q, He W, Matell G, Pirskanen R, Magnusson Y, Eng H, Lefvert AK. T and B lymphocytes reacting with the extracellular loop of the β2-adrenergic receptor (β2AR) are present in the peripheral blood of patients with myasthenia gravis. Clin. Exp. Immunol. 1996; 103:133–140.
Meyer SE, Stull JT. Cyclic AMP in skeletal muscle. Ann. NY Acad.Sci. 1971; 185:433–448.
Elfellah MS, Reid JL. The role of skeletal muscle β-adrenoreceptors in the regulation of plasma potassium. J. Auton. Pharmac. 1987; 7:175–184.
Marooned CD, Meadow JC. The effect of adrenaline on the contraction of human muscle. J. Physiol. 1970; 207:429–448.
Sjogaard G. Water and electrolyte fluxes during exercise and their relation to muscle fatigue. Acta Physiol. Scand. 1986; 128:129–136.
Cross RJ, Jackson JC, Brooks WH, Sparks DL, Markesbery WR, Roszman TL. Neuroimmunomodulation: impairment of humoral immune responsiveness by 6-hydroxydopamine treatment. Immunology 1986; 57:145–152.
Depelchin A, Letesson JJ. Adrenaline influence on the immune response II. its effects through action on the suppressor T cells. Immunol. Lett. 1981; 3:207–213.
Lu C-Z, Link H, Mo X-A, etal. Anti-presynaptic membrane receptor antibodies in myasthenia gravis. J. Neurol. Sci. 1991; 102: 39–45.
Yi Q, Pirskanen R, Lefvert AK. Presynaptic membrane receptor-reactive T lymphocytes in myasthenia gravis. Scand J Immunol. 1996; 43:81–87.
Grunewald J, Åhlberg R, Lefvert AK, DerSimonian H, Wigzell H, Jansson CH. Abnormal T cell expansion and V gene usage in myasthenia gravis patients. Scand.J.Immunol 1991; 34:161–168.
Castleman B. The pathology of the thymus gland in myasthenia gravis. Ann. NY Acad. Sci. 1966; 135:496–503.
Engel WK, Trotter JL, McFarlin DE, McIntosh CL. Thymic epithelial cell contains acetylcholine receptor. Lancet 1977;1:1310–1311.
Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Müller-Hermelink HK. Pathogenesis of myasthenia gravis: Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am. J. Pathol. 1988; 130:268–280.
Vincent A, Scadding GK, Thomas HC, Newsom-Davis J. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1978; 1:305–307.
Melms A, Schalke BCG, Kirchner T, Müller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis: Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenie patients. J. Clin. Invest. 1988; 81:902–908.
Papatestas AE, Genkins G, Kornfeld P, etal. Effects of thymectomy in myasthenia gravis. Ann. Surg. 1987; 206: 79–88.
Åhlberg R, Yi Q, Pirskanen R, etal. The effect of thymectomy on autoreactiv T-and B-lymphocytes in myasthenia gravis. Submitted
Åhlberg R, Yi Q, Pirskanen R, etal. Treatment of myasthenia gravis with anti-CD4 antibody: Improvement correlates to decreased T-cell autoreactivity. Neurology 1994; 44: 1732–1737.
Herzog C, Walker C, Müller W, etal. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: 1. Effect on clinical course and circulating T cells. J. Autoimmun. 1989; 2:627–642.
Hiepe F, Volk H-D, Apostoloff E, von Baehr R, Emmrich F. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 1991; 338:1529–1530.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lefvert, A.K. (1997). T-Cell Derived Mechanisms in the Pathogenesis of Myasthenia Gravis. In: Marx, A., Müller-Hermelink, H.K. (eds) Epithelial Tumors of the Thymus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0033-3_27
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0033-3_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0035-7
Online ISBN: 978-1-4899-0033-3
eBook Packages: Springer Book Archive